Top Insights
Brensocatib, a drug Insmed licensed from AstraZeneca, met the main goal of a Phase 3 test in non-cystic fibrosis bronchiectasis. Insmed plans to seek regulatory approvals in this indication while also continuing to develop the small molecule for other inflammatory disorders.
The post Insmed’s Trial Results Pave Way for FDA Filing in a Lung Disease With No Approved Therapies appeared first on MedCity News.
Leave a comment